As of August 29, 2026, Monte Rosa Therapeutics's top three insider holders are Ali Behbahani (Director, 6.69Mn shares), Venture Capital Vi, L.P. Versant (TenPercentOwner, 5.65Mn shares), Venture Capital Vi, L.P. Versant (TenPercentOwner, 5.65Mn shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Ali Behbahani | Director | 0 | 6,692,298 | 6,692,298 | 50.6% | 06 Jul, 2026 |
| 2 | Venture Capital Vi, L.P. Versant | TenPercentOwner | 4,079,469 | 1,573,453 | 5,652,922 | 42.7% | 30 Oct, 2024 |
| 3 | Markus Warmuth | President Ceo | 585,038 | 0 | 585,038 | 4.4% | 17 Jul, 2026 |
| 4 | Sharon Townson | Chief Scientific Officer | 67,845 | 0 | 67,845 | 0.5% | 07 Jul, 2026 |
| 5 | Jennifer Champoux | Chief Operating Officer | 62,371 | 0 | 62,371 | 0.5% | 16 Jul, 2026 |
| 6 | Filip Janku | Chief Medical Officer | 60,612 | 0 | 60,612 | 0.5% | 01 Jul, 2026 |
| 7 | Philip Nickson | Chief Business Legal Officer | 55,000 | 0 | 55,000 | 0.4% | 10 Apr, 2026 |
| 8 | Matthew Bowen | Principal Accounting Officer | 25,904 | 0 | 25,904 | 0.2% | 07 Apr, 2026 |
| 9 | Edmund Dunn | Principal Accounting Officer | 22,554 | 0 | 22,554 | 0.2% | 05 Mar, 2026 |
| 10 | Chandra P. Leo | Director | 10,000 | 0 | 10,000 | 0.1% | 25 Mar, 2025 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 16 Jul, 2026 | Markus Warmuth | President Ceo | Disposed S | 9,500 | $23.18 | $220.22K | 585,038 | Direct |
| 15 Jul, 2026 | Jennifer Champoux | Chief Operating Officer | Acquired M | 4,351 | $3.98 | $17.32K | 66,722 | Direct |
| 15 Jul, 2026 | Jennifer Champoux | Chief Operating Officer | Disposed S | 4,351 | $23.38 | $101.73K | 62,371 | Direct |
| 15 Jul, 2026 | Jennifer Champoux | Chief Operating Officer | Disposed M | 4,351 | $0.00 | $0 | 26,947 | Direct |
| 06 Jul, 2026 | Sharon Townson | Chief Scientific Officer | Acquired M | 6,000 | $6.14 | $36.84K | 73,845 | Direct |
| 06 Jul, 2026 | Sharon Townson | Chief Scientific Officer | Disposed S | 5,600 | $23.25 | $130.20K | 68,245 | Direct |
| 06 Jul, 2026 | Sharon Townson | Chief Scientific Officer | Disposed S | 400 | $24.13 | $9.65K | 67,845 | Direct |
| 06 Jul, 2026 | Sharon Townson | Chief Scientific Officer | Disposed M | 6,000 | $0.00 | $0 | 197,290 | Direct |
| 01 Jul, 2026 | Ali Behbahani | Director | Disposed J | 1,000,000 | $0.00 | $0 | 6,692,298 | Indirect |
| 01 Jul, 2026 | Ali Behbahani | Director | Acquired J | 15,000 | $0.00 | $0 | 15,000 | Indirect |
| 01 Jul, 2026 | Ali Behbahani | Director | Disposed J | 15,000 | $0.00 | $0 | 0 | Indirect |
| 30 Jun, 2026 | Filip Janku | Chief Medical Officer | Acquired M | 5,407 | $13.41 | $72.51K | 66,019 | Direct |
| 30 Jun, 2026 | Filip Janku | Chief Medical Officer | Disposed S | 5,407 | $24.50 | $132.47K | 60,612 | Direct |
| 30 Jun, 2026 | Filip Janku | Chief Medical Officer | Disposed M | 5,407 | $0.00 | $0 | 81,093 | Direct |
| 29 Jun, 2026 | Filip Janku | Chief Medical Officer | Acquired M | 6,000 | $7.56 | $45.36K | 65,992 | Direct |
| 29 Jun, 2026 | Anthony M. Manning | Director | Acquired M | 10,000 | $4.16 | $41.60K | 10,000 | Direct |
| 29 Jun, 2026 | Filip Janku | Chief Medical Officer | Disposed S | 6,000 | $22.95 | $137.70K | 59,992 | Direct |
| 29 Jun, 2026 | Anthony M. Manning | Director | Disposed S | 10,000 | $23.11 | $231.10K | 0 | Direct |
| 29 Jun, 2026 | Filip Janku | Chief Medical Officer | Disposed M | 6,000 | $0.00 | $0 | 60,000 | Direct |
| 29 Jun, 2026 | Anthony M. Manning | Director | Disposed M | 10,000 | $0.00 | $0 | 2,100 | Direct |